Sequential Use of Sorafenib and Regorafenib in Hepatocellular Cancer Recurrence After Liver Transplantation: Treatment Strategies and Outcomes

Basit Öğe Kaydı
dc.authoridozbay, mehmet fatih/0000-0002-3883-4364
dc.authoridcil, timucin/0000-0002-5033-1479
dc.authoridBayram, Ertugrul/0000-0001-8713-7613
dc.authoridGULTURK, Ilkay/0000-0003-1998-3150
dc.authoridTEKER, FATIH/0000-0003-4693-6587
dc.authoridSendur, Mehmet/0000-0001-7021-6139
dc.authoridgeredeli, caglayan/0000-0002-3982-7465
dc.contributor.authorOzbay, Mehmet Fatih
dc.contributor.authorHarputluoglu, Hakan
dc.contributor.authorKaraca, Mustafa
dc.contributor.authorTekin, Omer
dc.contributor.authorSendur, Mehmet Ali Nahit
dc.contributor.authorKaplan, Muhammed Ali
dc.contributor.authorSahin, Berksoy
dc.date.accessioned2025-02-22T14:08:41Z
dc.date.available2025-02-22T14:08:41Z
dc.date.issued2024
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground and Aims: During liver transplantation, hepatocellular carcinoma (HCC) recurrence remains a critical challenge for patient survival. Targeted therapies, such as sorafenib and regorafenib, have been utilized to manage relapsed HCC in this unique setting. This study aimed to assess the efficacy of Sorafenib and Regorafenib in patients with HCC who experienced recurrence after liver transplantation. We focused on survival outcomes, treatment responses, and the management of side effects in this patient group. Methods: We conducted a retrospective analysis of 73 patients who experienced HCC recurrence post-liver transplantation between 2012 and 2022 across 11 oncology centers in Turkey. Patients were categorized according to Child-Pugh classification and treated with sorafenib as first-line therapy and Regorafenib in case of progression. Survival rates were analyzed using the Kaplan-Meier method, and risk factors were evaluated using Cox regression analysis. Results: Of the 73 patients included in the study, 62 were male (84.9%), and 11 were female (15.1%), with a mean age of 61.5 +/- 10.9 years. All patients received sorafenib as first-line treatment. Among patients who experienced progression with sorafenib or discontinued treatment due to toxicity, 45.2% (n = 33) continued treatment with regorafenib. The median progression-free survival (PFS1) time with sorafenib was 5.6 months, and the one-year survival rate was 24.3%. The median progression-free survival (PFS2) time with regorafenib, which was administered as second-line treatment, was also calculated as 5.9 months. Overall survival (OS) duration was determined as 35.9 months. The most common side effects associated with both drugs included fatigue, hand and foot syndrome, and hypertension. Significantly better survival outcomes were shown in the Child-Pugh A group compared to other patients. Conclusions: These results suggest that Sorafenib and Regorafenib treatments offer a survival advantage in patients with relapsed HCC post-transplantation. However, individualized treatment strategies and close follow-up are crucial for optimizing outcomes. Further studies are needed to refine therapeutic protocols and enhance the care of this specific patient group.en_US
dc.identifier.doi10.3390/cancers16223880
dc.identifier.issn2072-6694
dc.identifier.issue22en_US
dc.identifier.pmid39594835en_US
dc.identifier.scopus2-s2.0-85211074455en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.3390/cancers16223880
dc.identifier.urihttps://hdl.handle.net/11468/29565
dc.identifier.volume16en_US
dc.identifier.wosWOS:001364175500001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherMdpien_US
dc.relation.ispartofCancersen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzKA_WOS_20250222
dc.subjecthepatocellular carcinoma (HCC)en_US
dc.subjectliver transplantationen_US
dc.subjectsorafeniben_US
dc.subjectregorafeniben_US
dc.subjectpost-transplant recurrenceen_US
dc.titleSequential Use of Sorafenib and Regorafenib in Hepatocellular Cancer Recurrence After Liver Transplantation: Treatment Strategies and Outcomesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu